** Shares of gene therapy maker Sarepta Therapeutics SRPT.O fall 21.3% to $36.80 in aftermarket trade
** Company sees 2025 net product revenue of $2.3 billion to $2.6 billion, compared to previous expectation of $2.9 billion to $3.1 billion
** Company reports adjusted Q1 loss of $3.42/shr, vs analysts' average loss estimate of 95 cents/shr, according to data compiled by LSEG
** SRPT shares, along with those of other gene therapy developers, had plummeted earlier in the day after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research
** Up to last close, stock down 61.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.